Global Liver Institute
News
GLOBAL LIVER INSTITUTE
Global Liver Institute Frustrated by FDA GIDAC Committee Failure to Recognize Serious, Unmet Need of Liver Patients in Rejection of Obeticholic Acid for Pre-Cirrhotic Fibrosis Due to NASH
Despite acknowledging OCA met the endpoint established by the FDA of reducing fibrosis by at least one stage, GIDAC voted against approval for treatment for NASH.
GLI Calls for Passage of the Organ Procurement and Transplantation Act
Global Liver Institute is proud to support H.R. 2544, the Securing the U.S. Organ Procurement and Transplantation Network Act. This bipartisan legislation responds to the urgent need for reforming the Organ Procurement Transplantation Network (OTPN), breaking up the national monopoly contract so that the Health Resources Services Administration (HRSA) can run an open, competitive process and choose from the best of the best in each field (e.g., health policy, IT, logistics, patient safety) to save more lives.
Environmental Effects on the Liver: Toxicant-Associated Liver Disease
Since liver health is public health, it is important to consider how our surroundings affect our livers.
Global Liver Institute Applauds Dr. Monica Bertagnolli’s Nomination as Director of the National Institutes of Health
Global Liver Institute proudly supports President Biden’s nomination of Monica Bertagnolli, MD, to be the Director of the National Institutes of Health (NIH).
GLI Provides Comments on the NIDDK Advisory Council’s Report of the Health Disparities and Health Equity Working Group
Global Liver Institute provided comment on the Report of the Health Disparities and Health Equity Working Group of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Advisory Council supporting NIDDK’s recommendations.
NASH Patient Needs Gain Growing Attention
It is more crucial than ever to not only understand the latest developments in the field but also play an active role in them.
Working Together towards Change in Rare Liver Diseases
In this month’s edition, we feature the latest initiatives that GLI has taken part in to advocate for policy changes and highlight new innovations in the rare liver disease field to allow for better research opportunities and improved patient outcomes.
Notable ACA Preventive Services Impacted by U.S. District Court Ruling in Texas
On March 30, 2023, a judge in the U.S. District Court in the Northern District of Texas issued a final judgment in a court case challenging the Affordable Care Act’s (ACA) requirement that private health insurance plans cover preventive services without cost-sharing for their enrollees.
Crucial Preventive Liver Screenings Imperiled by Court Ruling
On March 30, 2023, a judge in the U.S. District Court in the Northern District of Texas issued a final judgment in a court case challenging the Affordable Care Act’s (ACA) requirement that private health insurance plans cover preventive services without cost-sharing for their enrollees.
ICER Midwest CEPAC Works to Keep Up with Well-Informed NASH Patient Advocates
On Friday, the Institute for Clinical and Economic Review (ICER) held a public hearing to review its draft assessment of Resmetirom and Obeticholic Acid (OCA) for Non-Alcoholic Steatohepatitis: Effectiveness and Value. While the evidence presented for both drugs was deemed effective in fibrosis regression, ICER inconsistently voted to show that there was only a net health benefit in favor of resmetirom, being superior to lifestyle management alone, and not in OCA.
Patient Groups Declare ICER Review of NASH Medication Causes More Uncertainty and Controversies Than It Resolves
Today, the Institute for Clinical and Economic Review (ICER) will hold a public hearing on its draft assessment of Resmetirom and Obeticholic Acid for Non-Alcoholic Steatohepatitis: Effectiveness and Value.
Global Conversations, System Transformation, and Effective Advocacy
After a whirlwind winter, the first quarter of 2023 has come to a close!